Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ONS 44th Annual Congress /
Treating ovarian cancer patients with PARP inhibitors

11th - 14th Apr 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.05.19
Views: 2189
Rating:

Kimberly Halla - Arizona Oncology Associates PC, Scottsdale, USA

Kimberly Halla speaks to ecancer at ONS 2019 about the role of PARP inhibitors in the ovarian cancer world.

She explains about the role of germline testing and somatic testing in determining treatment options for ovarian cancer patients, as well as highlighting some of the clinical trials in progress.

Kimberly explains that PARP inhibitors are providing ovarian cancer patients with longer progression free survival and are empowering patients by allowing them to take the oral therapy at home, giving them more time with their friends and family.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation